The 2025 Famous National Brands announcement ceremony is an annual event organized by the Vietnam Invention Association and the Institute of Patent & Technology Innovation Development. This is one of the most prestigious awards in the field of brand building and development in Vietnam, with strict evaluation criteria that include: financial capacity, business performance, customer satisfaction, innovation ability, social responsibility, and sustainable development orientation.

The program aims to honor strong brands that have contributed positively to the sustainable development of the national economy, have a significant influence in the market, and are trusted by consumers.

F.I.T Group Representative Receives the Award at the Ceremony.

Sharing about the award, Ms. Vu Thi Minh Hoai – CEO of F.I.T Group said: “The Top 10 Famous National Brands 2025 award is a well-deserved recognition for the continuous efforts of the entire F.I.T Group team over the past 18 years of development. This is not only an honor but also a great responsibility for us to remain committed to our mission of enhancing the quality of life with superior products and services.”

Ms. Hoai also emphasized: “We view our brand as the company’s greatest asset. Therefore, every step F.I.T Group takes is carefully calculated to ensure a harmonious balance between economic growth and social contributions.”

The “Top 10 Famous National Brands 2025” Award Adds to the Achievements of the Group’s 18-Year Development Journey.

Founded in 2007, F.I.T Group is now one of Vietnam’s leading multi-industry economic groups, operating in core fields such as pharmaceuticals, FMCG (fast-moving consumer goods), real estate, and agriculture. With a systematic development strategy and a professional team, F.I.T Group has gradually affirmed its position both in the domestic and international markets. After 18 years of establishment and development, the group now owns 17 affiliated and subsidiary companies, with total assets of VND 7,747 billion and equity capital exceeding VND 5,940 billion. F.I.T Group not only focuses on business effectiveness but also remains steadfast in its mission to elevate the quality of life, aiming for harmonious development between business and society.

The “Top 10 Famous National Brands 2025” award is not only a proud achievement but also a strong motivation for F.I.T Group to continue realizing its vision of becoming a prosperous, multi-industry group with differentiated, top-tier products and services, leading the way in enhancing the quality of life. A place that attracts talent and is honored by society.

The introduction of the official residence not only demonstrates the practical care of the Company’s leadership towards its workforce but also contributes to improving the effectiveness of accommodation arrangements for workgroups, guests, and employees traveling from other locations to work at the company’s headquarters or branches in Vinh Long.

Located in the center of Vinh Long City, the DCL official residence is situated on the bustling Nguyen Hue street, easily connected to administrative offices, factories, company offices, and other social amenities such as banks, supermarkets, and restaurants. This location not only facilitates easy travel but also contributes to improving the quality of life and daily activities for residents.

The DCL Official Residence has been operational since April 2025.

The official residence is scientifically arranged with a total of 9 rooms, including 2 fixed rooms reserved for permanent staff to ensure stability and comfort during their stay. The remaining 7 rooms are equipped with large beds (1.8m x 2m), each room serving up to 2 people, offering a spacious, clean, and well-equipped environment.

Each room is equipped with modern furniture and basic amenities such as air conditioning, refrigerators, desks, televisions, Wi-Fi, and private restrooms to ensure comfort and privacy for users. This is an important feature that helps employees rest easy after a long day of work, knowing they have a comfortable place to stay.

The DCL Official Residence is fully equipped with functional rooms, meeting the accommodation needs of employees.

Staying at the official residence helps employees optimize their time and expenses while fostering a sense of connection and sharing within the company. Employees can live together, creating a friendly and cooperative working environment.

The investment and operation of the official residence in Vinh Long is one of DCL’s strategic steps in caring for and developing its human resources. It reflects the company’s sustainable development philosophy, putting people at the center.

“The DCL leadership believes that a good working environment comes not only from modern offices and advanced technology but also from the little things, such as carefully considered places to eat and stay. The official residence will serve as a welcoming space for workgroups, guests, and will be a source of support for employees who are away from home,” said Ms. Vo Thi Hong Tham – Director of Administrative Affairs & External Relations at DCL.

With the operation of the official residence in Vinh Long, DCL continues to affirm its commitment to accompanying its staff on every development journey. This is an important part of its strategy to build a friendly, professional, and humane work environment—a place that attracts talent and is honored by society.

1. Hello Mr. Dang, it is known that you were recently praised by the leadership for a product improvement initiative that was recognized and led to effective results. Could you share more about this improvement?

Recently, I came up with the idea to improve the quality of the Vilanta product. I am very happy and proud that my initiative has been acknowledged by both the leadership and my colleagues.

Mr. Le Van Dang – Director of the Antibiotics and Syrup Factory

2. How has the improvement of the Vilanta product impacted the production line at the factory? What specific changes were made in the technology or production process? What was the most significant breakthrough in the process of improving Vilanta at the factory?

The liquid medicine production line has been equipped with modern devices, with Vilanta being one of the flagship products, along with Aluinum gel and Babemol syrup. However, the production of Vilanta did not meet the sales plan or market demand. For many years, there has always been a shortage of this product. The reason is that Vilanta is a non-sterile product and must meet specific standards for Total Aerobic Microorganisms (≤100 cfu/g) and Molds (≤10 cfu/g). With such stringent standards, we need to be very cautious during production to ensure the best quality. Therefore, the factory implemented improvements mainly in the production process, focusing on sterilization during each stage: preparation, packaging, and post-packaging.

3. What was the most important breakthrough in the process of improving Vilanta at the factory?

The most important breakthrough in the Vilanta improvement process came from a very simple philosophy: “for internal use – for external application,” learned from the experience of doctors and physicians when treating patients. Since Vilanta is a non-sterile drug, strict adherence to the following measures was necessary during production: controlling the production environment to ensure optimal conditions and minimize external contamination; and sterilizing the product from within to prevent and control the growth of internal microorganisms. Applying this solution, the factory successfully produced 20 consecutive batches of Vilanta, with 100% of the batches meeting the required microbiological and mold standards as per the registered specifications.

4. Has the Vilanta improvement led to improvements in productivity, cost, or production time?

The improvement in production mainly resulted in cost savings, specifically reducing production costs, which ultimately benefits consumers. In the future, the factory will continue to research ways to reduce production time and maximize productivity for Vilanta to address the ongoing shortage and better meet market demand.

Mr. Le Van Dang at the DCL Antibiotics Factory

5. In your opinion, how is digital transformation affecting the pharmaceutical production process at the factory?

Digital transformation is directly impacting the production process by improving product quality, increasing labor productivity, boosting output, reducing production costs, and upgrading the management of product quality.

6. What message would you like to share with all employees at the factory during this transformative period?

Innovating thinking and fostering creativity will help everyone apply them in their work, leading to positive results. When facing difficulties during the production process, we should focus on thinking of solutions to solve problems rather than making excuses for why something cannot be done. Innovate to survive and improve upon the current situation. We must face challenges directly with a positive mindset. Nothing is impossible. We already have a solid foundation of knowledge and experience, and as long as we continue to learn and apply new tools, success is within reach.

During the meeting, the AGM listened to and approved the 2024 performance reports from the Board of Directors, Executive Board, and Supervisory Board. It also reviewed and provided input on the 2025 business plan. Shareholders approved several proposals, including the 2025 business plan, the standalone and consolidated audited financial statements for 2024, the selection of the auditing firm for 2025, and other matters within the AGM’s authority.

In 2024, the pharmaceutical industry continued to face numerous challenges. In response, DCL focused on evaluating and forecasting business conditions to formulate strategic solutions for managing operations effectively. Backed by the strategic vision of F.I.T Group, effective investment project management, and the development of a nationwide distribution network, DCL maintained operational stability and achieved 95% of its revenue target as approved at the 2024 AGM. According to the audited 2024 consolidated financial statements, DCL’s total assets increased from VND 2,277 billion to over VND 2,424 billion, and shareholder equity rose from VND 1,450 billion to over VND 1,503 billion.

2024 also marked a year of recognition for DCL, as the company was honored with multiple prestigious awards, including: Top 20 Sustainable Development Enterprises and Top 50 Strong ASEAN Brands.

At the meeting, the AGM approved the resignation and election of new members to the Supervisory Board for the 2022–2027 term. Following an open voting process, Ms. Ngo Thu Trang and Ms. Le Thi Thuong were elected as new members of the Supervisory Board.

The AGM conducted an open vote to elect new members to the Supervisory Board.

Also during the session, shareholders approved the 2025 Business Plan, which outlines key performance indicators and strategic priorities.

The Board of Directors will intensify its guidance to the Executive Board, focusing on the company’s core operational areas and adopting flexible management strategies aligned with market conditions:

• Pharmaceutical Sector: In 2024, DCL launched a project to upgrade its Nonbetalactam Plant in Vinh Long to meet EU-GMP standards, with completion expected in 2025. This will support export expansion and improve revenue and profitability. Additionally, in Q2/2025, the company will break ground on a new EU-GMP-compliant pharmaceutical manufacturing facility in Long An. The project covers a total area of 50,000 square meters, divided into two phases: Phase 1 will build a plant for cancer drug production, and Phase 2 will construct high-tech biological drug facilities, plant-based capsule production lines, a central warehouse, and a cosmetics and personal care manufacturing plant.

• Medical Equipment Sector: In March 2025, Benovas Medical Equipment JSC inaugurated a new factory capable of producing 21.5 million units per month. This facility not only meets domestic demand but also meets quality standards for exports to Europe and the U.S. In response to increasing demand for medical devices, the factory is committed to stable product supply and plans to invest in new equipment to produce additional items such as test tubes, IV catheters, butterfly needles, and dialysis filters.

• Empty Capsule Production: The Vicancap manufacturing facility, equipped with advanced Canadian technology, is currently operating at full capacity to meet domestic and international orders. With rising demand for empty capsules in the pharmaceutical and functional food industries, DCL completed Phase 5 of its expansion with a VND 232.5 billion investment, increasing capacity by 2.8 billion capsules/year—raising total capacity to 11.6 billion capsules/year. In 2024, the company also obtained FDA certification for its hard gelatin capsule products manufactured at the Capsule Plant.

With a spirit of unity, responsibility, and innovation, the 2025 AGM concluded successfully, reaffirming the strong connection between company leadership and shareholders on the path to sustainable development. The strategic directions approved at the meeting not only serve as a roadmap for 2025 business operations but also reflect DCL’s ambition to rise as a prominent player in Vietnam’s and the region’s pharmaceutical and healthcare landscape. With a solid foundation, Cuu Long Pharmaceutical is confident in entering a new phase—more efficient, more innovative, and poised for breakthrough growth.

The program featured six competing teams, each representing a union group from different departments and divisions across the company. Each team played the role of a “master chef,” presenting dishes rich in hometown flavors, infused with creativity and team spirit. With skillful hands and harmonious collaboration, the teams transformed the kitchen area into a cultural space where flavor, emotion, and spirit were fully intertwined.

Beyond just cooking delicious dishes, the teams also demonstrated creativity and careful planning in their presentation. Each banquet table was meticulously arranged, from layout and color coordination to decorative themes, reflecting the unique identity of each trade union group. Every booth became not only a culinary artwork but also a miniature cultural signature, representing the unity and vitality of each department.

The event was not merely a cooking competition, but a meaningful occasion for members to connect, share, and bond. Every smile, every cheer, and each shared moment during preparation and participation helped strengthen the ties between colleagues. From flavorful dishes to cheerful laughter, the festival brought positive energy, rekindling love for the workplace and the collective journey shared by all employees.

Teams Presented Their Dish Concepts to the Judges

After an exciting competition and fair evaluation by the panel of judges, the Business Division’s trade union team won First Prize with their spicy chicken hotpot. The Operations Division team took Second Prize, and the Pharmaceutical Factory team earned Third Prize.

Ms. Vo Thi Hong Tham – Director of Administration & External Affairs at DCL – Presents Awards to the Teams

The 2025 Culinary Festival exemplifies Cuu Long Pharmaceutical’s commitment to fostering a friendly, united, and inspiring work environment—where each individual is heard, connected, and empowered to grow. When departmental boundaries are bridged through simple everyday moments—like cooking together, laughing, or simply chatting over good food—it is in those moments that corporate culture is nurtured through sincerity and mutual understanding.

This program is a concrete example of DCL’s cultural vision—emphasizing unity, human values, and the creation of a positive, sustainable work environment. It supports the company’s goal of becoming the most highly regarded Vietnamese pharmaceutical company by patients, partners, and employees—through innovative, accessible, and high-quality products and services.

Earth Day is a global movement that encourages communities to raise awareness and take action to protect the environment and promote green consumption. Initiated by the United Nations in 1970, Earth Day is observed annually on April 22, aiming to prevent climate change disasters and environmental degradation.

In response to Earth Day and in pursuit of its mission “Enhancing quality of life through excellent, safe, and environmentally friendly products and services,” Today Cosmetics is committed to researching, developing, and producing organic products made entirely from natural ingredients. These products not only bring health benefits to consumers but also contribute to environmental protection.

Some product categories exclusively manufactured by Today Cosmetics

The company currently specializes in producing personal care, home care, and cosmetic products, all developed under the green-clean-suitable criteria to meet the needs of Vietnamese consumers. Today, the company boasts eight core brands (Dr Clean, NuWHITE, Dr KOOL, ROSY, ROCKET, Tero, Tero Sinh Học, and G10) with hundreds of high-quality products recognized by experts and trusted by the public. Notably, Today Cosmetics has successfully applied multi-enzyme technology to its Golden Life and Tero Sinh Học product lines, contributing to the green consumption trend while ensuring health safety for the entire family.

In the near future, the company will focus on developing and making breakthroughs in the cosmetics sector. Key products such as shampoo, facial cleanser, moisturizer, and sunscreen will be produced using advanced technology to ensure high quality and effectiveness. These products feature natural, safe ingredients and are free from harmful chemicals, all offered at reasonable prices—making them highly suitable for the majority of Vietnamese consumers.

High-quality, nature-derived products researched and developed by Today Cosmetics

With a strong focus on green manufacturing, Today Cosmetics ensures that its production processes follow advanced technology standards, complying with GMP and ISO 9001:2015 certifications to minimize negative environmental impact. Covering a production area of 1,132 square meters, the company operates five production lines equipped with technology imported from Europe and South Korea.

The Today Cosmetics factory is equipped with state-of-the-art machinery, supporting the entire manufacturing process—from mixing using a variety of mixers ranging from 1 to 10 tons, to a dedicated mixing zone for insect spray solutions. The filling process utilizes various filling lines tailored to specific product types, ensuring hygiene, safety, and minimal environmental impact.

Moreover, all stages of production are strictly monitored by the QA/QC team—from raw material quality control, physicochemical testing, in-line quality checks, to final product evaluation—ensuring compliance with the high standards set by the Ministry of Health.

Aiming for green and sustainable development while adhering to both domestic and international environmental regulations, Today Cosmetics is committed to continuously researching and introducing new formulas that are proven effective through scientific reports and clinical studies. The goal is to deliver truly high-quality personal care, home care, and cosmetic products—contributing to the spread of the green consumption trend and promoting better health within the community.

The delegation was led by Mr. Nguyễn Toàn Thắng, CEO of Benovas Medical Equipment JSC, and Mr. Nguyễn Trọng Đức, Deputy CEO of Cuu Long Pharmaceutical JSC.

CMEF is one of the largest medical equipment fairs in Asia, bringing together thousands of enterprises and suppliers in the medical device and healthcare technology sectors from around the world. At this year’s event, the DCL and BMD delegation held direct working sessions with leading suppliers of medical equipment and manufacturing machinery that are in high demand both in Vietnam and globally. A key goal of the trip was also to identify potential partners to support BMD’s expansion and product development plans for 2025.

Mr. Nguyễn Toàn Thắng in discussion with partners at CMEF.

During the trip, the delegation reached preliminary agreements with two equipment suppliers, paving the way for formal procurement contracts to be signed as early as April 2025. These devices are essential to BMD’s plans to invest in and modernize its production lines, helping to accelerate the implementation of its OGSM (Objectives, Goals, Strategies, Measures) roadmap aimed at product diversification and increasing output to meet revenue targets.

Sharing his thoughts after the trip, Mr. Nguyễn Trọng Đức said: “Participating in CMEF not only gave us direct access to cutting-edge global technologies and equipment, but also allowed us to strengthen relationships with strategic partners. The agreements reached during this trip provide a crucial foundation for BMD’s investment projects this year, supporting our goals for sustainable growth in both output and revenue.”

The delegation meeting with a strategic partner at CMEF.

Discussing the purpose of the trip, Mr. Nguyễn Toàn Thắng added:
“We are entering a phase of strong development. Keeping up with the latest technologies and investing in modern equipment is not just about optimizing our production processes—it’s also a powerful lever to help BMD expand its market presence, boost production capacity, and meet increasingly high-quality standards in the healthcare industry.”

With a strategic vision and proactive approach to international integration, the 2025 CMEF mission was not only an opportunity for DCL and BMD to expand their global partnerships, but also a clear demonstration of their commitment to systematic investment in production infrastructure and product development. These bold and synchronized steps will form a solid foundation for BMD to realize its growth ambitions and progressively affirm its position as one of Vietnam’s leading medical equipment manufacturers, with a growing presence in the regional market.

Accompanying BMD, DCL continues to affirm its role as a pioneer and connector in the pharmaceutical and medical equipment industry—demonstrating adaptability, innovation, and a steadfast commitment to creating lasting value for the community and Vietnam’s healthcare sector.

During the meeting, shareholders listened to and approved the 2024 performance reports presented by the Board of Directors (BOD), the Executive Board, and the Supervisory Board. They also reviewed and provided input on the business plan for 2025. The AGM passed various proposals, including the 2025 business plan, the audited standalone and consolidated financial statements for 2024, the selection of an auditing firm for 2025 financial reports, and other matters within the authority of the AGM.

In 2024, despite ongoing economic challenges, F.I.T Group focused on adhering closely to its strategic action plans. The Group made product improvements, invested in factory and facility development, enhanced employee knowledge and experience, and launched digital transformation initiatives across the organization. According to the audited 2024 consolidated financial statements, F.I.T Group closed the year with total assets exceeding VND 7,747 billion.

Thanks to its impressive business results and impactful community contributions, F.I.T Group was honored with the Top 10 Outstanding Vietnamese Brands 2024 award.

The AGM heard reports on governance, business operations in 2024, and plans for 2025.

During the meeting, shareholders voted on the dismissal and election of several members of the Board of Directors and Supervisory Board. Accordingly, the AGM approved the resignation of certain individuals from the BOD and the Head of the Supervisory Board, and elected Mr. Đỗ Văn Thọ as a new BOD member and Mr. Đoàn Xuân Duy as a new Supervisory Board member.

Discussions during the meeting focused on production and business performance, progress on new factories by member companies, and 2024 financial results. The Chairman’s Panel and F.I.T Group’s leadership acknowledged and responded to all shareholder concerns in detail.

Looking ahead to the strategic direction for 2025 and beyond, F.I.T Group aims to expand its operations through organic growth and strategic acquisitions of promising companies. The Group seeks to own leading brands in essential goods sectors while also maintaining and enhancing partnerships with major domestic and international enterprises to boost its capabilities in governance, technology, engineering, and trade.

Speaking at the AGM, on behalf of the Board of Directors, Mrs. Nguyễn Thị Minh Nguyệt – Vice Chairwoman, recognized and praised the Group’s efforts in governance and business operations in 2024. She provided strong direction for the 2025 action plans:
“The company will continue to leverage its existing strengths to stay ahead and adapt to economic developments. We remain attuned to market trends to seize new investment opportunities and make full, effective use of our available financial resources.”

The 2025 AGM marks not only a key milestone in F.I.T Group’s development journey but also a bold affirmation of its ambition to rise and thrive in the new era. With a clear strategy, firm confidence, and unity among the BOD, leadership, and employees, F.I.T Group remains committed to continuous innovation and sustainable value creation. The Group is steadfast in its vision to become a prosperous, multi-sector corporation delivering premium, pioneering products and services that enhance quality of life and attract top talent, earning widespread societal recognition.

During the meeting, the General Shareholders’ Meeting listened to and approved: the activity report of the Board of Directors (BOD), the Supervisory Board (SB), and the General Director (CEO) for 2024, as well as the operational plan for 2025; the profit distribution plan for 2024 and the business plan for 2025; the financial report for 2024;…

TSC’s Annual General Shareholders’ Meeting was held online.

In 2025, amidst the fluctuations in both domestic and international economic and political landscapes, the company has proactively invested in upgrading technology and improving production processes to increase product value, thereby enhancing its competitiveness in the global market. Within TSC’s ecosystem, the company has clearly identified its goal to focus on developing high-performance business sectors such as bottled water (Vikoda) and agricultural product processing (Westfood). At the same time, TSC is intensifying the development of cosmetic products following the “green consumption” trend, which is environmentally friendly (FIT Cosmetics).

The 2025 Annual General Shareholders’ Meeting of TSC was successfully held.

In addition, the company is also focusing on investing in research and development (R&D) activities and expanding its distribution network, which contributes to strengthening its core competitiveness and driving growth in both revenue and profit in the near future. Notably, the Westfood Hau Giang factory project, under the Western Export Food Processing Joint Stock Company (a subsidiary of TSC), has completed the legal procedures and began construction in June 2024. It is expected to reach an output capacity of 30,000 tons per year, further solidifying the company’s stature in the production and business sector. At the same time, TSC is reaffirming and reinforcing its responsibility towards the environment and the local community by ensuring workplace safety and environmental hygiene in its factories.